To include your compound in the COVID-19 Resource Center, submit it here.

Intarcia gets CRL for Type II diabetes candidate ITCA 650

FDA issued a complete response letter to an NDA for ITCA

Read the full 116 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE